Anixa Biosciences (ANIX) announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback